{
  "id": "biosimilar",
  "title": "Biosimilar",
  "lang": "en",
  "source_lang": "en",
  "summary": "A biosimilar is a biological medicine shown to be highly similar to an approved reference product, with no clinically meaningful differences in safety or effectiveness.",
  "category": "health",
  "subcategory": "drugs",
  "type": "concept",
  "aliases": [
    "Biosimilar medicine",
    "biosimilar biological product"
  ],
  "generated_at": "2026-11-03",
  "model": "pro/gpt-6.1-sol",
  "url": "https://aiwiki.page/en/biosimilar/",
  "translations": {
    "zh-Hans": {
      "url": "https://aiwiki.page/zh/biosimilar/",
      "json": "https://aiwiki.page/zh/biosimilar.json"
    }
  },
  "sections": [
    {
      "heading": "",
      "text": "A biosimilar is a biological medicine developed to be highly similar to an already authorized biological medicine, known as its reference product. Approval requires evidence that any differences between the products do not produce clinically meaningful differences in safety, purity, or potency, including therapeutic effectiveness. Biosimilars include versions of insulins, growth factors, and monoclonal antibodies used in conditions such as cancer, rheumatoid arthritis, and inflammatory bowel disease.\n\nUnlike most conventional drugs, biological medicines are produced using living systems and have structures that can be affected by their manufacturing processes. A biosimilar therefore cannot generally be established through the same relatively straightforward chemical comparison used for a conventional generic drug. Its development instead relies on a detailed comparison of molecular structure and biological function, supported by pharmacological and, where needed, clinical studies.\n\nBiosimilars create competition after the relevant regulatory exclusivities and intellectual property protections permit market entry. Their significance extends beyond the replacement of individual products: they affect pharmaceutical manufacturing, regulatory science, treatment access, prescribing, and health financing. Their approval rests on the principle that a well-characterized product can draw on existing knowledge about a reference medicine without repeating its entire original development programme."
    },
    {
      "heading": "Molecular identity and the meaning of similarity",
      "text": "Most established biosimilars contain therapeutic proteins. These range from relatively small proteins, such as insulin, to large antibodies with several interacting structural domains. A typical immunoglobulin G antibody has a molecular mass of about 150 kilodaltons, compared with about 180 daltons for aspirin. Size alone does not determine regulatory complexity, but it illustrates why identifying the chemical composition of a small molecule and characterizing a therapeutic antibody are substantially different tasks.\n\nA protein’s activity depends on more than its amino-acid sequence. Folding, disulfide bonds, electrical charge, aggregation, and chemical modifications can influence its behavior. Many proteins also carry carbohydrate chains added by the production cell through glycosylation. The resulting medicine is a population of closely related molecular forms rather than a perfectly uniform collection of molecules. Even successive batches of an established reference medicine display controlled variation.\n\nFor most recombinant protein biosimilars, the amino-acid sequence is expected to match that of the reference product, while some other molecular attributes may vary within scientifically justified limits. The central question is whether a difference can affect clinical performance. For example, certain sugar structures on an antibody can influence binding to receptors on immune cells and thereby alter cell-killing activity. A difference in such an attribute may be important even when the antibody binds its principal target normally. Conversely, a small difference in an attribute with no relevant functional effect may be acceptable.\n\nThis makes biosimilarity a comparative scientific conclusion, not a claim that two products are indistinguishable by every available test. Modern analytical methods can detect differences that are too small, or biologically irrelevant, to change a medicine’s effects. Regulatory assessment evaluates the nature, magnitude, and functional consequences of differences rather than requiring an absence of every measurable distinction.\n\nA biosimilar is also distinct from a deliberately modified successor medicine, sometimes called a “biobetter.” A protein redesigned to remain in circulation longer, bind a different target, or produce greater biological activity is not ordinarily eligible for approval merely as a biosimilar. Such modifications may create a useful medicine, but they change the regulatory question from demonstrating similarity to establishing the properties of a new product. Likewise, a biological medicine marketed without an adequate head-to-head comparison is not necessarily a biosimilar in the regulatory sense, even if it contains a protein with the same name."
    },
    {
      "heading": "Manufacturing and control of product quality",
      "text": "Biosimilar development begins with the reference medicine, but its manufacturer generally does not have access to the originator’s proprietary cell line, production process, or complete manufacturing history. The developer must establish an independent process capable of producing a consistently similar product. This commonly involves engineering cells with the relevant DNA, selecting a production cell line, optimizing culture conditions, and designing purification and formulation steps.\n\nMammalian cells, including Chinese hamster ovary cells, are widely used to produce complex antibodies, whereas some simpler proteins can be made in bacteria or yeast. The choice of host influences protein folding, carbohydrate structures, and the impurities that must be removed. Culture temperature, nutrient availability, oxygen supply, and harvest timing can also change the distribution of molecular variants. Manufacturing therefore determines characteristics that cannot simply be corrected by testing the finished product.\n\nAfter production, purification removes host-cell proteins, residual DNA, process chemicals, and unwanted forms of the therapeutic protein. Relevant processes may include chromatography, filtration, and validated viral clearance steps. Formulation then establishes conditions that preserve stability during storage and administration. A biosimilar may contain different inactive ingredients from its reference product, provided these differences are compatible with the applicable requirements and do not undermine the demonstration of biosimilarity.\n\nDevelopers identify critical quality attributes: measurable characteristics that may affect safety or effectiveness. These can include biological potency, aggregate content, particular glycan structures, and residual impurities. The manufacturing process must keep these attributes within justified limits. A product cannot compensate for inadequate molecular similarity merely by producing an apparently similar result in a relatively insensitive clinical study.\n\nReference-product sampling is an important part of this work. Comparing multiple batches helps distinguish normal reference-product variability from a genuine difference in the proposed biosimilar. Samples may differ in manufacturing date, remaining shelf life, or commercial presentation, all of which must be considered when interpreting analytical results.\n\nOnce approved, a biosimilar remains subject to manufacturing controls, stability requirements, and assessment of significant process changes. This resembles the comparability exercises required when an originator changes its own manufacturing process, although establishing biosimilarity between independently developed products is a distinct regulatory exercise. Manufacturing authorization, inspection, and batch consistency remain necessary throughout a product’s life cycle; similarity at the time of approval does not replace ongoing quality assurance."
    },
    {
      "heading": "Comparative analytical and clinical evidence",
      "text": "Biosimilar assessment uses a totality-of-evidence approach. Evidence is assembled progressively, with later studies directed at uncertainty that remains after earlier comparisons. Structural and functional characterization forms the foundation because these methods can often identify product differences more sensitively than a large clinical efficacy trial. The purpose is not to demonstrate anew that the biological target is therapeutically useful, but to establish that the proposed product can rely on the reference medicine’s established clinical record.\n\nAnalytical comparisons can examine amino-acid sequence, higher-order structure, charge variants, carbohydrate profiles, degradation products, and aggregates. Mass spectrometry, chromatography, and other complementary methods provide different views of the molecule. Functional assays test activities relevant to the mechanism of action, such as binding to a target, blocking a signaling pathway, stimulating cell proliferation, or recruiting immune-cell activity. For an antibody with several relevant functions, a single target-binding assay may be insufficient.\n\nComparative pharmacokinetic studies evaluate how the body handles the products. Common measurements include peak blood concentration and total exposure, often expressed as the area under the concentration–time curve. Study populations are selected to provide a sensitive comparison and may include healthy volunteers when ethically and scientifically appropriate. The familiar bioequivalence interval of 80–125% for certain exposure ratios is often relevant, but the specific design and acceptance criteria depend on the product and regulatory context.\n\nPharmacodynamic measurements assess biological effects. A sufficiently sensitive and well-understood biomarker may provide strong comparative evidence. For a granulocyte colony-stimulating factor such as filgrastim, changes in absolute neutrophil count are closely connected to the medicine’s biological activity. Suitable pharmacodynamic evidence can sometimes reduce the need for a separate comparative efficacy trial.\n\nWhen a comparative clinical trial is required, its design differs from the original trial establishing that a new medicine works. An equivalence study generally seeks to exclude differences larger than prespecified clinically acceptable margins in either direction. Failure to find a statistically significant difference is not, by itself, proof of equivalence. A randomized controlled trial must have an appropriate population, endpoint, sample size, and analysis capable of addressing similarity.\n\nClinical requirements are consequently product-specific. Some development programmes include substantial efficacy trials; others can resolve the relevant uncertainty through strong analytical, functional, pharmacokinetic, and pharmacodynamic evidence. Additional clinical studies cannot reliably rescue a product with unexplained structural or functional differences. Conversely, repeating large trials may add little information when more sensitive comparisons have already addressed the plausible sources of clinical difference."
    },
    {
      "heading": "Extrapolation to indications not directly studied",
      "text": "A reference medicine may be authorized for several diseases, doses, age groups, or combinations with other treatments. A biosimilar does not necessarily need a separate comparative efficacy trial in every one of those settings. Extrapolation is the regulatory acceptance of one or more additional indications on the basis of the complete evidence supporting biosimilarity and a scientifically justified assessment of how that evidence applies.\n\nThe justification considers the mechanism of action in each indication, target binding, relevant biological functions, distribution within the body, pharmacokinetics, and immunogenicity. It also considers whether different patient populations or concomitant medicines could reveal clinically important differences. Extrapolation is therefore neither an automatic entitlement nor a simple assumption that all diseases respond in the same way.\n\nAntibodies illustrate the complexity. The same antibody may act through direct target blockade, depletion of target-bearing cells, or several immune-mediated mechanisms. The relative contribution of these activities may differ between a malignant disease and an inflammatory disorder. If a particular immune-effector function matters in one indication, analytical and functional comparisons must adequately address it even when the principal comparative clinical trial was conducted in another disease.\n\nInfliximab biosimilars were an important early example. The first European approvals of the infliximab biosimilar CT-P13 in 2013 supported multiple indications, although its initial comparative clinical development focused on rheumatoid arthritis and ankylosing spondylitis. Extension to inflammatory bowel diseases depended on the broader evidence package and assessment of mechanisms, not solely on a claim that the studied and unstudied diseases were interchangeable. Subsequent clinical studies and routine-use data added experience in bowel disease, but the original regulatory logic was comparative and mechanistic.\n\nThis approach reflects how biological medicines are regulated more generally. Major manufacturing changes to a reference product may also be accepted through comparability evidence without repeating efficacy trials for every authorized indication. Biosimilar extrapolation applies related scientific reasoning to an independently manufactured product, while requiring its own demonstration of similarity.\n\nThe indications listed in a biosimilar’s authorization can nevertheless differ from those of its reference medicine. Patent restrictions, periods of protected use, application strategy, or the scope of the submitted evidence may limit the authorized label. An omitted indication does not by itself establish a biological difference, just as extrapolation does not create authorization for every conceivable use. The approved product information defines the indications actually granted by the relevant regulator."
    },
    {
      "heading": "Regulatory development and international frameworks",
      "text": "Europe established the first major dedicated regulatory pathway for biosimilars. European Union legislation adopted in 2004 provided the legal framework, followed by scientific guidance from the European Medicines Agency. In 2006, the European Commission authorized Omnitrope, a somatropin product, as the first biosimilar approved through that framework. Early approvals involved proteins such as growth hormone, epoetins, and filgrastim; later approvals extended to more complex antibodies.\n\nIn the United States, the Biologics Price Competition and Innovation Act of 2009, enacted in March 2010 as part of the Affordable Care Act, created an abbreviated licensure pathway under section 351(k) of the Public Health Service Act. The legislation distinguished biosimilarity from the additional legal category of interchangeability. The Food and Drug Administration approved the first US biosimilar, Zarxio, a filgrastim product referencing Neupogen, in March 2015.\n\nAn important US transition occurred on 23 March 2020, when certain protein products previously approved as drugs, including insulin products, became regulated as biological products under the Public Health Service Act. This enabled subsequent applications referencing those products to use the biosimilar pathway. In July 2021, insulin glargine-yfgn, marketed as Semglee, became the first FDA-approved interchangeable biosimilar insulin.\n\nThe World Health Organization issued guidelines on similar biotherapeutic products in 2009 and later revised its guidance to reflect accumulated experience and advances in characterization. Its work provides a scientific framework that national authorities can adapt, but WHO guidance does not itself confer marketing authorization in a country. National systems differ in application procedures, naming, clinical-data expectations, substitution rules, and the availability of regulatory resources.\n\nRegulators generally require an appropriate reference product authorized on the basis of a complete dossier. A comparison with a product that has not itself been adequately established can undermine the entire evidentiary chain. When a developer uses reference-product samples sourced from another jurisdiction, additional bridging evidence may be necessary to connect those samples to the locally recognized reference medicine.\n\nTerminology has not always been consistent across markets. Expressions such as “follow-on biologic,” “subsequent-entry biologic,” and “similar biotherapeutic product” have been used in different systems. Some older biological copies entered markets before modern biosimilar standards existed. Consequently, the presence of a familiar active-substance name is not sufficient to establish that a product has undergone a contemporary comparative assessment. The authorization pathway and supporting evidence determine its regulatory status."
    },
    {
      "heading": "Therapeutic classes and clinical applications",
      "text": "Biosimilars encompass several therapeutic classes with distinct molecular and clinical characteristics. Growth factors were among the earliest examples. Filgrastim stimulates the production of neutrophils and is used in settings including chemotherapy-associated neutropenia and mobilization of blood-forming stem cells. Pegfilgrastim is a longer-acting form in which attachment of polyethylene glycol changes the molecule’s persistence in the body. A pegfilgrastim biosimilar must therefore characterize both the protein and the relevant features of its chemical modification.\n\nEpoetin products stimulate red-cell production and have established uses in certain forms of anemia, including anemia associated with chronic kidney disease. Their glycosylation affects clearance and biological activity, making carbohydrate characterization particularly important. Somatropin biosimilars provide another early class, used in specified growth disorders. These examples demonstrate that biosimilarity concerns the behavior of the complete medicinal product, not simply recognition of the same protein sequence.\n\nBiosimilar insulins occupy a distinctive clinical setting because insulin treatment depends on the interaction of molecule, concentration, dosing regimen, and delivery system. Products may be supplied in vials, cartridges, or prefilled pens. Demonstrating molecular and pharmacological similarity does not mean that every delivery device has the same operating instructions. The clinical role of a biosimilar insulin is also determined by which insulin it references: a basal insulin analogue is not equivalent to a rapid-acting insulin merely because both treat diabetes mellitus.\n\nAntibody biosimilars include tumor necrosis factor inhibitors such as infliximab and adalimumab, and other proteins used in inflammatory disease, such as etanercept, a receptor–Fc fusion protein. Their authorized uses can encompass rheumatoid arthritis, psoriasis, and inflammatory bowel disease, depending on the molecule and jurisdiction. These products act on specific inflammatory pathways rather than functioning as general replacements for all medicines used in those conditions.\n\nIn oncology, biosimilars include trastuzumab, bevacizumab, and rituximab products. Trastuzumab targets HER2 and is used in selected HER2-positive cancers; bevacizumab targets vascular endothelial growth factor; rituximab targets CD20 on B cells and has applications in certain blood cancers and autoimmune diseases. These differences govern which binding and cellular assays are most informative during development.\n\nBiosimilars have also entered ophthalmology through products referencing ranibizumab and aflibercept, which inhibit vascular endothelial growth factor signaling. For medicines administered into the eye, formulation, sterility, particulate control, and delivery characteristics have particular importance. Across therapeutic areas, biosimilarity preserves the reference medicine’s established role; it does not imply that different biological targets, routes of administration, or treatment schedules are clinically interchangeable."
    },
    {
      "heading": "Switching, interchangeability, and pharmacy substitution",
      "text": "Several related terms describe different decisions. Switching usually means changing a patient from one biological product to another during treatment. Interchangeability can describe a scientific conclusion about using products in place of one another, but it also has a specific statutory meaning in the United States. Substitution commonly refers to dispensing one product instead of another without a new prescribing decision, under the rules of the relevant jurisdiction.\n\nIn the United States, an interchangeable biosimilar must meet requirements beyond the statutory demonstration of biosimilarity. These include an expectation that it will produce the same clinical result as the reference product in any given patient. For a product administered more than once, the legal standard also addresses whether alternating or switching increases risks of diminished effectiveness or safety compared with continued use of the reference product. An FDA interchangeability designation can permit pharmacy substitution, subject to state law.\n\nThe designation does not mean that an interchangeable biosimilar is more effective, purer, or generally safer than a biosimilar without that designation. Both have met the biosimilarity standard. Historically, specific switching studies were prominent in US interchangeability development. Regulatory thinking has evolved as analytical methods and experience have expanded, and the necessity of additional switching data is a distinct question from the underlying legal standard.\n\nIn 2022, the European Medicines Agency and the Heads of Medicines Agencies issued a joint statement supporting the scientific interchangeability of EU-approved biosimilars with their reference medicines or equivalent biosimilars. Decisions about substitution at the pharmacy level nevertheless remain with individual European countries. A European statement on interchangeability therefore does not create a single uniform dispensing rule across the continent.\n\nClinical switching evidence includes randomized studies, extension studies, and observational data. The Norwegian NOR-SWITCH trial, published in 2017, enrolled 482 patients across six inflammatory diseases and compared continued originator infliximab with switching to CT-P13 over 52 weeks. It supported noninferiority for the pooled study population under its prespecified design, but it was not powered to establish a separate conclusion for every disease subgroup. That distinction matters when interpreting frequently cited switching results.\n\nTreatment changes can also be influenced by expectations, communication, device differences, and administrative arrangements. The nocebo effect describes adverse symptoms or perceptions influenced by negative expectations rather than a specific harmful pharmacological difference. It is one possible explanation for some discontinuations in open-label switch programmes, not a reason to dismiss reported symptoms. Evaluation separates objective disease activity, adverse reactions, usability issues, and expectation-related effects rather than treating all post-switch events as evidence of product failure."
    },
    {
      "heading": "Immunogenicity, safety surveillance, and traceability",
      "text": "Therapeutic proteins can stimulate the immune system to produce antibodies against the medicine. These anti-drug antibodies may have no detectable clinical consequence, accelerate clearance, reduce effectiveness, or, less commonly, contribute to hypersensitivity reactions. Some antibodies neutralize the medicine’s activity. In unusual circumstances, they can also interfere with a corresponding natural protein in the body. Immunogenicity is therefore a concern for reference biological medicines as well as biosimilars.\n\nRisk depends on several interacting factors: protein sequence, aggregates, impurities, formulation, route of administration, dosing pattern, the patient’s disease, and accompanying treatment. Different antibody-detection assays also have different sensitivity and tolerance to circulating drug. A simple comparison of published antibody percentages from unrelated studies can therefore be misleading. Head-to-head testing with validated methods is more informative than comparing numbers generated under incompatible conditions.\n\nA historically important episode involved antibody-mediated pure red-cell aplasia associated with an epoetin alfa reference product, particularly after a formulation change and subcutaneous use. Reports increased in the late 1990s and early 2000s. The event was not a general demonstration that biosimilars were unsafe; rather, it showed that formulation, packaging interactions, and administration conditions can influence the safety of any biological medicine. It also strengthened attention to comparative immunogenicity and post-authorization monitoring.\n\nBefore approval, comparative studies examine anti-drug antibodies and relevant clinical consequences over an appropriate observation period. Such studies cannot reliably exclude every rare or delayed event. Post-marketing pharmacovigilance therefore remains essential. Spontaneous reports, patient registries, healthcare databases, and targeted studies can detect patterns not apparent in a development programme.\n\nTraceability is especially important when several products share an active-substance name. Recording the actual product and, when available, its batch number helps investigators distinguish a class-wide effect from a product-specific or batch-specific problem. Naming conventions vary: the United States uses distinguishing four-letter suffixes for many biological product names, while other jurisdictions rely on combinations of brand name, international nonproprietary name, and batch information.\n\nObservational safety comparisons also require care. Patients may be switched because of procurement changes, worsening disease, or changes in insurance coverage, and those circumstances can affect outcomes independently of the medicine. Confounding, incomplete product identification, and unequal follow-up can distort comparisons. Reliable assessment combines product-level traceability with appropriate study methods and examines the established risks of the biological class rather than assuming that every event following a switch was caused by biosimilarity."
    },
    {
      "heading": "Competition, access, and development economics",
      "text": "The economic rationale for biosimilars is to introduce competition without requiring each manufacturer to repeat the reference medicine’s entire discovery and clinical development programme. Nevertheless, development remains demanding. Extensive characterization, complex manufacturing facilities, process validation, comparative studies, and regulatory submissions create substantial costs. This helps explain why biosimilar competition has often developed differently from the highly competitive markets for many small-molecule generics.\n\nPatent expiry alone does not determine market entry. Multiple patents may cover the active molecule, manufacturing methods, formulations, devices, or particular uses. Regulatory exclusivity is a separate protection. In the United States, the statutory framework generally prevents approval of a biosimilar until 12 years after first licensure of the reference product, with restrictions on application submission during the first four years. Litigation and settlement agreements can further affect launch dates without changing the scientific determination of biosimilarity.\n\nThe relationship between approval and actual availability is therefore indirect. The first US adalimumab biosimilar was approved in 2016, but US biosimilar competition for adalimumab began in 2023. In Europe, adalimumab biosimilars entered the market in 2018. These differing timelines illustrate the effects of legal and commercial arrangements rather than a corresponding difference in the basic biology of the products.\n\nPurchasing systems strongly influence uptake. Hospital tenders can concentrate volume in a small number of suppliers, sometimes producing large price reductions. In other systems, reimbursement rules, insurance formularies, rebates, and distribution contracts shape which product is used. A medicine with a lower published price does not necessarily have the lowest net acquisition cost, and savings to a payer do not automatically translate into lower out-of-pocket spending for every patient.\n\nCompetition can improve treatment access by reducing expenditure per treated patient or allowing a health service to treat additional patients within a fixed budget. The scale of that effect depends on baseline access, diagnostic capacity, infusion services, prescribing rules, and whether savings remain available for care. Biosimilars cannot by themselves resolve all barriers to complex treatment, especially where cold-chain infrastructure or specialist services are limited.\n\nMarket sustainability introduces a further tension. Very low procurement prices may reduce short-term expenditure while making participation unattractive to some suppliers. Conversely, limited competition can weaken price pressure and leave buyers dependent on a small supply base. Economic analysis therefore distinguishes immediate discounts from longer-term effects on entry, manufacturing capacity, and supply resilience. Assessment commonly considers total treatment costs—including administration, monitoring, devices, and implementation—rather than the acquisition price of an individual vial or injection alone."
    }
  ],
  "links": [
    "insulin",
    "monoclonal-antibody",
    "cancer",
    "rheumatoid-arthritis",
    "inflammatory-bowel-disease",
    "intellectual-property",
    "health-financing",
    "protein",
    "glycosylation",
    "dna",
    "bacteria",
    "spectroscopy",
    "pharmacokinetics",
    "pharmacodynamics",
    "biomarker",
    "clinical-trial",
    "randomized-controlled-trial",
    "world-health-organization",
    "neutropenia",
    "anemia",
    "chronic-kidney-disease",
    "diabetes-mellitus",
    "psoriasis",
    "immune-system",
    "pharmacovigilance"
  ],
  "sources": [],
  "license": "https://creativecommons.org/licenses/by/4.0/"
}